■ Graybug Vision has presented preclinical study results for GB-401, a novel injectable depot formulation of a proprietary beta-adrenergic antagonist prodrug, as a potential sustained-delivery treatment of up to 6 months for primary open-angle glaucoma. The study evaluated the in vitro and in vivo performance of GB-401, including pharmacokinetics, ocular safety, and IOP-lowering efficacy, and showed that GB-401 achieved sustained ocular drug levels and reduced IOP in experimental animal models after a single intravitreal or subconjunctival injection.

“We are encouraged by these preclinical study results and look forward to evaluating the potential of GB-401 as a new long-term treatment for patients with primary open-angle glaucoma in a phase 1/2a first-in-human trial,” said Frederic Guerard, CEO of Graybug Vision.